FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V, PDGFRA Gene Amplification
Conditions
Keywords
Compassionate use
Brief summary
Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis. Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)
Detailed description
This program is being offered on a patient by patient basis while phase 3 studies with crenolanib are ongoing. Institutional Review Board-/Independent Ethics Committee approval must be granted before, The experimental intervention will be administered over 28-day cycles. Compassionate use of crenolanib will be limited such that it does not interfere with the supply need for phase 3 studies. There must be adequate understanding of the indication for the requested use.
Interventions
Sponsors
Arog Pharmaceuticals, Inc.
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Subject must have a serious life threatening cancer with FLT3/PDGFRa mutation or PDGFRa amplification who has exhausted all other treatment options * Subject and their partner (if adults) must use 2 forms of contraception during study and for 3 months following last dose of study drug
Exclusion criteria
* Subject is eligible for enrollment in an ongoing clinical trial * Subject has any condition which, in the investigator's opinion makes the subject unsuitable for participation
Countries
Italy
Contacts
Primary ContactVinay Jain, MD
Outcome results
None listed